# A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

> **NCT01394016** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 225 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT01394016
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-07
- **Primary completion:** 2014-05-29
- **Final completion:** 2022-04-12
- **Target enrollment:** 225 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01394016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01394016, "A Phase 1 Study of LY2835219 In Participants With Advanced Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01394016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*